このページの翻訳は実験的なもので、現在開発中です。お待ちしております

Jiangsu Nhwa Pharmaceutical マネジメント

マネジメント基準チェック /34

Jiangsu Nhwa Pharmaceutical'sの CEO はJiaquan Sunで、 May2013年に任命され、の在任期間は 11.08年です。は、会社の株式の0.071%を直接所有しており、その価値はCN¥ 17.15M 。経営陣と取締役会の平均在任期間はそれぞれ11.1年と17.2年です。

主要情報

Jiaquan Sun

最高経営責任者

CN¥4.8m

報酬総額

CEO給与比率	n/a
CEO在任期間	11.3yrs
CEOの所有権	0.07%
経営陣の平均在職期間	11.3yrs
取締役会の平均在任期間	17.4yrs

経営陣の近況

Recent updates

CEO（最高経営責任者

Jiaquan Sun (48 yo)

11.3yrs

在職期間

CN¥4,800,000

報酬

Mr. Jiaquan Sun has been General Manager at Jiangsu Nhwa Pharmaceutical Co., Ltd. since May 31, 2013 and has been its Non-Independent Director since April 1, 2019. Mr. Sun serves as General Manager of Jian...

リーダーシップ・チーム

名称	ポジション	在職期間	報酬	所有権
Jiaquan Sun	GM & Non-Independent Director	11.3yrs	CN¥4.80m	0.070% CN¥ 17.8m
Gangsheng Li	Chief Financial Officer	1.9yrs	CN¥633.60k	データなし
Qing Fu	Deputy GM & Non-Independent Director	11.3yrs	CN¥200.00k	3.93% CN¥ 998.2m
Zengliang Chen	Deputy GM & Non-Independent Director	11.3yrs	CN¥200.00k	3.93% CN¥ 998.2m
Ziliang Yang	Deputy GM & Non-Independent Director	11.3yrs	CN¥200.00k	3.69% CN¥ 938.3m
Bao Zhou Duan	Deputy GM & Secretary	11.3yrs	CN¥413.70k	0.0053% CN¥ 1.3m

11.3yrs

平均在職期間

59yo

平均年齢

経験豊富な経営陣: 002262の経営陣は経験豊富で経験豊富です（平均在職期間は11.1年）。

取締役

名称	ポジション	在職期間	報酬	所有権
Jiaquan Sun	GM & Non-Independent Director	14.3yrs	CN¥4.80m	0.070% CN¥ 17.8m
Qing Fu	Deputy GM & Non-Independent Director	17.4yrs	CN¥200.00k	3.93% CN¥ 998.2m
Zengliang Chen	Deputy GM & Non-Independent Director	17.4yrs	CN¥200.00k	3.93% CN¥ 998.2m
Ziliang Yang	Deputy GM & Non-Independent Director	17.4yrs	CN¥200.00k	3.69% CN¥ 938.3m
Pengsheng Sun	Non-Independent Chairman of the Board	17.4yrs	CN¥250.00k	4.87% CN¥ 1.2b
Guangji Wang	Independent Director	5.5yrs	CN¥50.00k	データなし
Yu Lan Li	Independent Director	2.4yrs	CN¥50.00k	データなし
Fengshou Wang	Chairman of the Supervisory Board	17.4yrs	データなし	データなし
Xinglei Jia	Member of the Supervisory Board	17.4yrs	データなし	データなし
Xiao Chen Qian	Employee Representative Member of Supervisory Board	17.4yrs	データなし	データなし
Xiaoxing Yin	Independent Director	2.4yrs	CN¥50.00k	データなし
Guoxiang Chen	Independent Director	2.4yrs	CN¥50.00k	データなし

17.4yrs

平均在職期間

61yo

平均年齢

経験豊富なボード: 002262の取締役会は経験豊富で経験豊富です ( 17.2年の平均在任期間)。

Jiangsu Nhwa Pharmaceutical マネジメント

マネジメント 基準チェック /34

主要情報

経営陣の近況

Jiangsu Nhwa Pharmaceutical Co., LTD, Annual General Meeting, Apr 24, 2024

High number of new directors

Jiangsu Nhwa Pharmaceutical Co., LTD Approves the Election of Chen Guoxiang and Li Yulan as Independent Directors

Insufficient new directors

Insufficient new directors

Jiangsu Nhwa Pharmaceutical Co., LTD, Annual General Meeting, Apr 29, 2022

Recent updates

Now 20% undervalued

Second quarter 2024 earnings released: EPS: CN¥0.36 (vs CN¥0.31 in 2Q 2023)

Jiangsu Nhwa Pharmaceutical Co., LTD to Report First Half, 2024 Results on Jul 31, 2024

Now 21% overvalued

Full year 2023 earnings released: EPS: CN¥1.03 (vs CN¥0.89 in FY 2022)

Jiangsu Nhwa Pharmaceutical Co., LTD, Annual General Meeting, Apr 24, 2024

Investor sentiment deteriorates as stock falls 17%

Jiangsu Nhwa Pharmaceutical Co., LTD to Report Fiscal Year 2023 Results on Mar 30, 2024

Third quarter 2023 earnings released: EPS: CN¥0.34 (vs CN¥0.30 in 3Q 2022)

New minor risk - Share price stability

Second quarter 2023 earnings released: EPS: CN¥0.31 (vs CN¥0.25 in 2Q 2022)

Jiangsu Nhwa Pharmaceutical Co., LTD to Report First Half, 2023 Results on Jul 31, 2023

Jiangsu Nhwa Pharmaceutical Co., Ltd. Receives Formal Approval from the National Medical Products Administration for OLINVYK

Full year 2022 earnings released: EPS: CN¥0.89 (vs CN¥0.79 in FY 2021)

Third quarter 2022 earnings released: EPS: CN¥0.30 (vs CN¥0.26 in 3Q 2021)

Investor sentiment improved over the past week

Second quarter 2022 earnings released: EPS: CN¥0.25 (vs CN¥0.24 in 2Q 2021)

Second quarter 2022 earnings released: EPS: CN¥0.25 (vs CN¥0.24 in 2Q 2021)

High number of new directors

Jiangsu Nhwa Pharmaceutical Co., LTD Approves the Election of Chen Guoxiang and Li Yulan as Independent Directors

First quarter 2022 earnings released: EPS: CN¥0.19 (vs CN¥0.17 in 1Q 2021)

Insufficient new directors

Insufficient new directors

Full year 2021 earnings released: EPS: CN¥0.79 (vs CN¥0.72 in FY 2020)

Jiangsu Nhwa Pharmaceutical Co., LTD, Annual General Meeting, Apr 29, 2022

Jiangsu Nhwa Pharmaceutical Co., LTD, Annual General Meeting, Apr 29, 2022

Jiangsu Nhwa Pharmaceutical Co., Ltd Proposes Cash Dividend for 2021

Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat

Third quarter 2021 earnings released: EPS CN¥0.26 (vs CN¥0.21 in 3Q 2020)

Second quarter 2021 earnings released: EPS CN¥0.24 (vs CN¥0.21 in 2Q 2020)

Jiangsu Nhwa Pharmaceutical Co., Ltd Announces 2020 Final Profit Distribution Plan to Be Implemented (A Shares), Payable on 02 June 2021

First quarter 2021 earnings released: EPS CN¥0.17 (vs CN¥0.14 in 1Q 2020)

New 90-day low: CN¥13.53

Full year 2020 earnings released: EPS CN¥0.72 (vs CN¥0.66 in FY 2019)

Revenue beats expectations

New 90-day low: CN¥14.10

Investor sentiment deteriorated over the past week

Jiangsu Nhwa Pharmaceutical Co., LTD to Report Fiscal Year 2020 Results on Mar 12, 2021

New 90-day low: CN¥15.46

New 90-day high: CN¥18.50

Third quarter earnings released

Third-quarter earnings released: Revenue misses expectations

Jiangsu Nhwa Pharmaceutical Co., LTD to Report Q3, 2020 Results on Oct 26, 2020

New 90-day low: CN¥15.34

New 90-day low - CN¥15.61

New 90-day high - CN¥18.57

Jiangsu Nhwa Pharmaceutical Co., LTD to Report First Half, 2020 Results on Jul 31, 2020

CEO（最高経営責任者

在職期間

報酬

リーダーシップ・チーム

平均在職期間

平均年齢

取締役

平均在職期間

平均年齢

マネジメント基準チェック /34